Search results
Bivalirudin (Angiox®) Plasma Control
Quality control of clotting assays proposed for measuring bivalirudin concentrations in plasma (especially ref. CK002K, CK002L and 220202).
Argatroban (Argatra®) Control Plasma
Quality control of clotting assays proposed for measuring argatroban concentrations in plasma (especially ref. CK002K, CK002L).
Factor V Deficient Plasma
Measurement of factor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor II (Prothrombin) Deficient Plasma
Measurement of Factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor X Deficient Plasma
Measurement of factor X (FX or stuart factor) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FX deficient plasma is required
Factor VII Deficient Plasma
Measurement of factor VII (FVII / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FVII deficient plasma is required
HEMOCLOT Quanti. V-L
Quantitative measurement of Factor V Leiden, resistant to the action of activated protein C (APC resistance), for diagnosing patients carrying the R506Q FV mutation (Factor V Leiden), or any FV mutant resistant to APC.
Factor XII Deficient Plasma
Measurement of factor XII (FXII or factor hageman) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent).For any in vitro protocol or research study where a source of human FXII deficient plasma is required.
Factor XI Deficient Plasma
Measurement of factor XI (FXI or factor rosenthal) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent). For any in vitro protocol or research study where a source of human FXI deficient plasma is required
Factor VIII Deficient Plasma
Measurement of actor VIII (FVIII) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent). For any in vitro protocol or research study where a source of human FVIII deficient plasma is required.